Posted by Michael Wonder on 24 Aug 2022
Access criteria for new COVID-19 treatment announced
25 August 2022 - PHARMAC has today confirmed the access criteria for the first preventative medicine for COVID-19, tixagevimab and cilgavimab (Evusheld), for severely immunocomprfomised New Zealanders.
Evusheld is available now in hospitals and will be available in the community from mid-September. “We are taking a phased approach to allow additional time for community implementation to be developed with the sector.”
